New and emerging treatment options for neuropathic pain.

摘要: A large number of neuroanatomical, neurophysiologic, and neurochemical mechanisms are thought to contribute the development maintenance neuropathic pain (NP). As a result, corresponding wide range treatments have been employed treat patients with NP, including antiepileptic drugs, opioid analgesics, tricyclic antidepressants, selective serotonin reuptake inhibitors, serotonin-norepinephrine N-methyl-D-aspartate receptor antagonists, cholecystokinin adenosine, lipoic acid, cannabinoids, isosorbide dinitrate, dronabinol, capsaicin, protein kinase C aldose reductase VR-1 modulators. Many these compounds limited by marginal efficacy clinically significant adverse events; few evaluated in well-controlled, large-scale clinical trials. At present, only agents approved for treatment painful diabetic peripheral neuropathy postherpetic neuralgia lidocaine patches 5%, duloxetine, gabapentin, pregabalin. Of these, pregabalin is indicated both conditions.